Justin West is a physician and father of three. His youngest son, Andrew, was diagnosed with KCNT1-related epilepsy at 9 months of age. He is director of clinical medicine at the KCNT1 Epilepsy Foundation, working with researchers and industry to identify and evaluate potential therapeutics.
Justin West
President and director of clinical medicine
KCNT1 Epilepsy Foundation
From this contributor
Progress amid setbacks in drug trials for rare forms of epilepsy: Q&A with Justin West
Despite grave side effects, it’s vital to keep developing treatments for rare genetic forms of childhood epilepsy, says West, president of the KCNT1 Epilepsy Foundation and father of a son with the condition.
Progress amid setbacks in drug trials for rare forms of epilepsy: Q&A with Justin West
By
Calli McMurray
30 August 2023 | 6 min read
Explore more from The Transmitter
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
By
Paul Middlebrooks
21 October 2026 | 1 min read
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
By
Claudia López Lloreda
21 October 2026 | 9 min read
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
By
Natalia Mesa
20 October 2026 | 7 min read